top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.641 -0.009 (-0.56%)
Streaming Delayed Price Updated: 1:56 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,274,342
Open 1.660
Bid (Size) 1.640 (7,600)
Ask (Size) 1.650 (12,500)
Prev. Close 1.650
Today's Range 1.600 - 1.690
52wk Range 0.5150 - 1.960
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
From Ocugen
Via GlobeNewswire

Performance

YTD
+18.9%
+18.9%
1 Month
+17.2%
+17.2%
3 Month
+7.2%
+7.2%
6 Month
+46.5%
+46.5%
1 Year
+116.9%
+116.9%

More News

Read More
News headline image
Ocugen Stock Is Surging Today: What's Driving The Action? ↗
Via Benzinga
News headline image
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
From Ocugen
Via GlobeNewswire
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
From Ocugen
Via GlobeNewswire
News headline image
OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder ↗
Via Stocktwits
News headline image
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen (OCGN) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
OCUGEN INC (NASDAQ:OCGN) Reports Mixed Q3 2025 Results Amid Clinical Pipeline Progress ↗
Via Chartmill
News headline image
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at Industry and Investor Conferences in October 2025
From Ocugen
Via GlobeNewswire
News headline image
Forecasting The Future: 4 Analyst Projections For Ocugen ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Why Ocugen Stock Zoomed 12% Higher Today ↗
Via The Motley Fool
News headline image
Ocugen Shares Are Trading Higher Monday: What's Going On? ↗
Via Benzinga
News headline image
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire

Frequently Asked Questions

Is Ocugen, Inc. - Common Stock publicly traded?
Yes, Ocugen, Inc. - Common Stock is publicly traded.
What exchange does Ocugen, Inc. - Common Stock trade on?
Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocugen, Inc. - Common Stock?
The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
What is the current price of Ocugen, Inc. - Common Stock?
The current price of Ocugen, Inc. - Common Stock is 1.641
When was Ocugen, Inc. - Common Stock last traded?
The last trade of Ocugen, Inc. - Common Stock was at 01/23/26 01:56 PM ET
What is the market capitalization of Ocugen, Inc. - Common Stock?
The market capitalization of Ocugen, Inc. - Common Stock is 422.20M
How many shares of Ocugen, Inc. - Common Stock are outstanding?
Ocugen, Inc. - Common Stock has 422M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page